ABSTRACT Dopamine (DA) produces a natriuretic/diuretic response in the kidney by mcnisms that are still not well understood. There is some ination that DA2 receptors may be involved in mating the effects of DA, but little is known regarding the nature of this receptor in the kidney. Autoraigaphic localation of [3Hspiperone, a DA2 anta t, i ed that high-density binding was r ic to inner meduilary ting ducts (IMCDs) Exogenous dopamine (DA) produces a natriuretic/diuretic response in a variety of species, including humans (1, 2). The natriuretic effects of DA are generally thought to be due to an increase in renal blood flow and glomerular filtration rate (1) but may include direct tubular effects since low doses of DA increase urine output and urinary sodium excretion without altering renal hemodynamics (3-5). Although the mechanism of action ofDA within the kidney is not resolved, the effects ofDA on the kidney are blocked by DA receptor antagonists (2, 6, 7). DA receptors have been classified in the central nervous system as D1 and D2 (8) and in the periphery as DA1 and DA2 (9). A great deal of evidence indicates that vascular and tubular DA1 receptors are involved in mediating the actions of DA on the kidney (6, 7). Further support for a tubular site ofaction for DA comes from autoradiographic localization of DA1 receptors in rat kidney, which indicates that the highest levels are found in the proximal tubules (10, 11).
Exogenous dopamine (DA) produces a natriuretic/diuretic response in a variety of species, including humans (1, 2) . The natriuretic effects of DA are generally thought to be due to an increase in renal blood flow and glomerular filtration rate (1) but may include direct tubular effects since low doses of DA increase urine output and urinary sodium excretion without altering renal hemodynamics (3) (4) (5) . Although the mechanism of action ofDA within the kidney is not resolved, the effects ofDA on the kidney are blocked by DA receptor antagonists (2, 6, 7) . DA receptors have been classified in the central nervous system as D1 and D2 (8) and in the periphery as DA1 and DA2 (9) . A great deal of evidence indicates that vascular and tubular DA1 receptors are involved in mediating the actions of DA on the kidney (6, 7) . Further support for a tubular site ofaction for DA comes from autoradiographic localization of DA1 receptors in rat kidney, which indicates that the highest levels are found in the proximal tubules (10, 11) .
Much less is known regarding the role of DA2 receptors in mediating the renal responses to DA. Spiperone, a central nervous system D2 antagonist, blocks the DA-stimulated increase in renal blood flow and sodium excretion in isolated perfused rat kidney (4) . Bromocriptine, a DA2 agonist, has been reported to increase renal blood flow and singlenephron glomerular filtration rate in the rat (12, 13 (22) and are described in detail elsewhere (T.H. and D.P.H., unpublished data). Cells were maintained 1 day in Dulbecco's modified Eagle's medium/F-12 medium supplemented with 10% fetal calf serum and then changed to a fully defined K-1 medium.
Prostaglandin E2 (PGE2) Production. IMCD cells were maintained in 24-well culture dishes and incubated in triplicate for 60 min with medium containing 100 ,AM pargyline, 0.01% ascorbic acid, and the appropriate drugs, and the medium was assayed for PGE2 content by radioimmunoassay. Values were expressed as means ± SEM of triplicate culture wells based on experiments repeated 3-12 times. .M' (Fig. 1A) and was seen in autoradiograms as thin tubular-like elements converging toward the tip of the papilla (Fig. 1D) . Higher-resolution autoradiography using emulsion-coated coverslips (11) (Fig. 3) .
DA and the DA2 agonist bromocriptine have been reported to increase urinary excretion of PGE2 (24), the highest levels of which are produced in the kidney inner medulla (25) . Known stimulators of PGE2 synthesis, such as arachidonic acid and bradykinin, stimulated PGE2 production from primary cultures of IMCD cells (Fig. 4) . Bromocriptine also increased PGE2 production, but the D2 agonist LY171555 failed to stimulate PGE2 release, consistent with the inability of LY171555 to compete for [3H]spiperone binding (Table 1) . DA (100 ,M) stimulated PGE2 production from IMCD cells -2-fold. The effect was blocked by domperidone, a peripheral DA2 antagonist, but not by other antagonists, including Sch 23390 (DA1), propranolol (,B-adrenergic), or phentolamine (a-adrenergic). The cyclooxygenase inhibitor indomethacin completely blocked DA-stimulated PGE2 production.
DISCUSSION
[3H]Spiperone has been used extensively to study D2 receptors in the central nervous system (26 (17, 26) , although the binding affinity was 15-500 times lower in the inner medulla than in rat striatum (17, 26) . The specificity of the [ (29), using different D2 receptor probes than were used here, also failed to detect a positive hybridization signal with kidney RNA. Likewise, the oligonucleotide probes selected here for hybridization were complementary to the putative transmembranespanning regions (IV and VII) of the D2 receptor, regions that are highly conserved among aminergic receptors. Thus, it is highly unlikely that the negative hybridization results were due to the kidney inner medulla DA receptor being an alternatively spliced variant of the brain D2 receptor.
Relevant to this discussion is a recent report by Sokoloffet al. (31) , which was published while this manuscript was under review. These authors reported the cloning of a DA receptor from brain, which they have termed the D3 receptor. This receptor is 52% homologous to the D2 receptor overall and 75% homologous in the putative transmembrane-spanning regions. The D3 receptor has a somewhat different pharmacological profile compared to the D2 receptor and does not appear to be negatively linked to adenylyl cyclase, as is the D2 receptor (31) . Interestingly, the D3 receptor may be expressed in the kidney, since a weak signal was detected by the polymerase chain reaction (31) . Examination of the competition binding data, however, indicates that the pharmacological profile of the D3 receptor is much more similar to the brain D2 receptor than the IMCD DA receptor. In addition, although quinpirole (LY171555) was 100-fold more selective for the D3 receptor than the D2 receptor (31) , it was the least potent of any dopaminergic agonist used here as a competitor for [3H]spiperone binding and it was also ineffective at stimulating PGE2 production from IMCD cells. In addition, the D2 receptor oligonucleotide probes used here for the RNA hybridization analyses were -71% complementary (32/45 and 30/42 nucleotides) to the nucleotide sequence of the D3 receptor mRNA and may have been expected to hybridize with kidney inner medulla RNA ifthe D3 receptor was expressed in the inner medulla. Taken together, these negative pieces of evidence would suggest that the brain D3 receptor and the kidney inner medulla DA receptor are not identical.
Thus, the most likely explanation for the lack of hybridization seen here with D2 receptor probes and kidney inner medulla RNA is that the kidney [3H]spiperone binding site represents a DA receptor encoded by a different gene than the brain D2 receptor. The marked differences in the pharmacology of the [3H]spiperone binding in the kidney inner medulla compared to the striatal D2 receptor suggests that the two receptors are distinct, whereas the fact that both bind [3H]spiperone and are a similar size suggests that the kidney inner medulla DA receptor is D2-like. Thus, on the basis of our findings, we speculate that the kidney inner medulla DA receptor represents a newly discovered DA receptor subtype, designated here as DA2K. This is consistent with recent speculation as to the existence of additional peripheral DA receptor subtypes (32) . There is some precedence in support of multiple D2/DA2 receptor genes, as three distinct a2-adrenergic receptor genes with a heterogenous pattern of tissue expression have been cloned (33) .
We further determined that the DA2K receptor in the inner medulla was functional, since bromocriptine and DA, but not LY171555, stimulated PGE2 production in IMCD cells, and that the DA-mediated stimulation could be blocked selectively by the DA2 antagonist domperidone. Additional support that the DA-stimulated PGE2 production was via the DA2K receptor comes from the demonstration that [3H]domperidone binds to IMCD cells in vitro with a pharmacological profile similar to the profile for [3H]spiperone binding to kidney inner medulla membranes (T.H. and D.P.H., unpublished data). The DA stimulation of PGE2 production in IMCD cells is consistent with a report by Yoshimura et al. (24) in which they showed that DA and the DA2 agonist bromocriptine increased urinary excretion of PGE2. PGE2 is the most abundant renal prostaglandin in the rat and the highest levels are produced in the inner medulla (25) . PGE2 is known to be a potent physiological antagonist of the hydroosmotic effects of vasopressin in the collecting duct and also directly inhibits sodium reabsorption in the distal nephron (25) . The demonstration that DA stimulates PGE2 production, together with the known physiological properties of DA and PGE2 as vasodilators and inhibitors of sodium reabsorption, suggests that these agents may act in concert to modulate water and electrolyte excretion in the inner medulla. Attempts to block DA-mediated renal responses by inhibition of prostaglandin synthesis, however, have led to conflicting results (34) but should be reexamined in light of the present findings.
The presence of DA2K receptors in the distal nephron raises new possibilities regarding the action of DA within the kidney. DA is known to be produced intrarenally by uptake and decarboxylation of L-dopa by the proximal tubules in proportion to sodium load (35) (36) (37) . Indeed, the major portion of urinary DA excreted appears to be derived from the intrarenal conversion of plasma L-dopa (38) . The local synthesis ofDA together with the presence of renal DA receptors has led to the concept that DA may be an intrarenal natriuretic substance (5, 35, 39) . It is possible to speculate that DA, produced by the proximal tubules under conditions of increased sodium load, could filter down and bind to DA2K receptors on IMCD cells. Activation of DA2K receptors could then inhibit vasopressin activity either directly, as has been shown for DA in rabbit cortical collecting ducts (40) , or indirectly through release of PGE2. A reduction in vasopressin activity would result in a decrease in water reabsorption by the collecting ducts. Thus, the IMCD DA2K receptor may be topologically situated to play a significant role in mediating the natriuretic/diuretic effects of DA, whether formed intrarenally or administered exogenously.
